Laboratory Services News & Publications
Important Testing Notification
Please see important testing notification regarding potential for false-positive Norovirus with Gastrointestinal Infection Array (GIIA) Testing.
Testing Updates
July 6, 2026
Important Test Announcement: Somatic Disease RNA Sequencing
June 16, 2026
Important Test Announcement: Reference Lab Testing Updates
June 16, 2026
Important Test Announcement: Fungal Antibodies Extended Panel Serum
May 26, 2026
Important Test Announcement: IBD Precis
March 24, 2026
Important Test Announcement: T Cell Senescence and Exhaustion Panel with TBNK by Flow Cytometry (TSEPP)
March 16, 2026
Important Test Announcement: Vitamin B5 (Pantothenic Acid), Serum Plasma
March 16, 2026
Important Test Announcement: Urine Drugs of Abuse Screen, BHP and Lewis Center
March 10, 2026
Important Test Announcement: Expanded In-House Allergen Testing
February 24, 2026
Important Test Announcement: B-ALL MRD Day 29 Test Update
February 9, 2026
Important Test Announcement: Sendout Test Updates
January 20, 2026
Important Test Announcement: Pro-Brain Natriuretic Peptide (pro-BNP), Thyroglobulin Antibody, Thyrotropin Receptor Antibody, Test Methodology Update
January 13, 2026
Important Test Announcement: Updated Specimen Requirements for Ethylene Glycol
January 13, 2026
Important Test Announcement: Reference Lab Testing Updates
New Reference Ranges
January 20, 2025
Changes in reference ranges for Test Methodology Update
October 20, 2025
Changes in reference range for Glucagon Testing
August 12, 2025
Changes in reference range for Amikacin (Pre and Post dose)
July 8, 2025
Changes in reference range for Reticulocyte Count
October 15, 2024
Changes in reference range for Quantitative Factor XIII
Sexually Transmitted Infection Testing Resources
Nationwide Children’s Laboratory Services provides resources for health care professionals, including a Sexually Transmitted Infections Practice Tool. Visit Clinical Tools for a complete list.
Included in the current STI Practice Tool are recommendations from the Centers for Disease Control and Prevention (CDC) regarding “opt-out” testing policies.
According to CDC recommendations, providers might consider opt-out chlamydia and gonorrhea screening (i.e., the patient is notified that testing will be performed unless the patient declines, regardless of reported sexual activity) for adolescent and young adult females during clinical encounters. Cost-effectiveness analyses indicate that opt-out chlamydia screening among adolescent and young adult females might substantially increase screening, be cost saving and identify infections among patients who do not disclose sexual behavior.
Nationwide Children’s has provided sample opt-out letters that providers may download and customize for patient/parent communication:
Patient Letter (Customizable)
Download:
Parent Letter (Customizable)
Download: